Strategies for Navigating Socioeconomic Factors In Reproductive Medicine
Socioeconomic factors impacting patients seeking infertility treatment are highlighted.
EP: 1.Clinician Challenges In Infertility Diagnosis
EP: 2.Emerging Trends and Technology Within Reproductive Medicine Landscape
EP: 3.Evaluating Access to Care and Service Coverage Associated With Reproductive Medicine
EP: 4.Availability of Coverage Impacting Patients Seeking Infertility Treatment
EP: 5.Strategies for Navigating Socioeconomic Factors In Reproductive Medicine
EP: 6.Optimizing Health Benefit Design and Patient Outcomes In Infertility Management
The following is a perspective from Joseph Chervenak, MD, MBA.
The medical expert discusses the variation in infertility prevalence, emphasizing disparities across different regions and the unique challenges faced by certain states. Dr Chervenak, based in Manhattan, highlights the abundance of board-certified reproductive embryology and infertility specialists in the area compared to other states. The disparities are attributed to factors such as political influence, cultural acceptance of assistive reproduction, and the distribution of fellowships for training reproductive and endocrinologists.
The focus then shifts to addressing access disparities in infertility care, especially for cancer patients, through strategies like increasing counseling, education, and awareness. He advocates for financial support for disadvantaged patients, particularly those diagnosed with cancer, who could benefit from fertility preservation techniques like freezing their eggs.
Legal and regulatory considerations in the heavily regulated field of reproductive care and infertility are discussed, with attention to recent legal developments such as Roe v. Wade and the potential impact on assisted reproductive technology (ART). The need for vigilance in monitoring how these legal changes affect fertility medicine practices in different states is emphasized. Overall, his insights underscore the importance of addressing regional variations, access disparities, and legal considerations to enhance the quality of infertility care and support for patients.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
